{"id":"W2138871107","doi":"10.1056/nejmoa1402584","title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":4611,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Genentech; Shionogi; Imperial College London; National Institute for Health and Care Research; Veracyte; Galecto; Massachusetts Medical Society; Royal Brompton and Harefield NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; Gilead Sciences; FibroGen; Biogen; Ikaria; Celgene; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Nintedanib; Medicine; Idiopathic pulmonary fibrosis; Placebo; Exacerbation; Vital capacity; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial; Pathology; Lung; Lung function","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}